-
1 Comment
Akoustis Technologies, Inc is currently in a long term downtrend where the price is trading 14.3% below its 200 day moving average.
From a valuation standpoint, the stock is 680.8% more expensive than other stocks from the Technology sector with a price to sales ratio of 197.3.
Akoustis Technologies, Inc's total revenue rose by 152.5% to $1M since the same quarter in the previous year.
Its net income has dropped by 27.9% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 17.1% to $-10M since the same quarter in the previous year.
Based on the above factors, Akoustis Technologies, Inc gets an overall score of 1/5.
| CurrencyCode | USD |
|---|---|
| Exchange | NASDAQ |
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | nan |
|---|---|
| PE Ratio | None |
| Target Price | 32.5 |
| Market Cap | 1B |
| Dividend Yield | None |
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AKTS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
